Clinical Trial Update: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial of ICP-488 in moderate-to-severe plaque psoriasis has completed, reporting efficacy, safety, pharmacokinetics and pharmacodynamics data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ICP-488

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Moderate to Severe Plaque Psoriasis | Phase 2 | Status: COMPLETED